326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
Oct 10, 2024
auto_awesome
John Maraganore, a biotech veteran and former CEO of Alnylam Pharmaceuticals, talks about his startup City Therapeutics and recent Nobel Prize awards. He touches on the evolution of RNA interference and its entrepreneurial challenges. Megan Molteni, a STAT reporter, dives into He Jiankui's controversial work and his new cryptocurrency backer, discussing the ethical implications of gene editing. The conversation also explores the ongoing debates around AI's future, capturing both optimistic and pessimistic perspectives in tech.
John Maraganore emphasizes the necessity of innovative clinical trial designs for the success of gene silencing drugs at City Therapeutics.
The resurfacing of He Jiankui highlights the ethical dilemmas in embryo editing amidst growing commercial interests in gene editing technologies.
Deep dives
John Maragonori's New Venture and Biotech Insights
John Maragonori, a notable figure in biotechnology, has launched a new company called City Therapeutics, aiming to focus on gene silencing drugs that utilize smaller RNA molecules. Drawing from his extensive experience at Alnylam Pharmaceuticals, he discusses the necessity of innovation within clinical trial designs, emphasizing that modernizing these protocols is essential for success in drug development. Maragonori contrasts the approach of smaller, entrepreneurial companies like City with larger biotech firms, highlighting the advantage of being able to direct capital and resources towards specific, innovative ideas. He believes that such focused efforts can create new growth opportunities within the rapidly evolving RNA interference field, positioning City Therapeutics as a significant contender in the market.
The Journey of He Jiankui and CRISPR Controversy
He Jiankui gained infamy in 2018 for his unethical work involving CRISPR gene editing on human embryos, which resulted in the birth of genetically modified children. After serving prison time for his actions, he resurfaced with ambitions of continuing similar experiments, now focusing on editing embryos to reduce Alzheimer's disease risk. This return sparked discussions about the ethics of embryo editing, particularly in light of his past, which was riddled with ethical violations and scientific misconduct. Advocates within certain tech circles, however, view his work as an opportunity to advance gene editing technology, despite public outcry and substantial skepticism surrounding his methodologies.
The Emergence of Ryan Shea in Controversial Gene Editing
Ryan Shea, a cryptocurrency entrepreneur, has become intertwined with He Jiankui's work, drawn in by a personal connection to Alzheimer's disease and an apparent desire to explore the commercial potential of germline editing. Shea's background in blockchain technology raises eyebrows as it presents a stark contrast to the traditional fields of biotech and medicine, illuminating the increasingly blurred lines between technology and healthcare. Discussions reveal that Shea envisions embryo editing not just as a scientific endeavor but as a lucrative market opportunity, indicating a shift toward monetizing genetic interventions. This perspective raises critical ethical concerns regarding the implications of commodifying such profound medical technology amid widespread advocacy for safer approaches.
Effective Accelerationism and the Future of Biotechnology
The philosophy of Effective Accelerationism (EAC) has begun to shape conversations in Silicon Valley surrounding new technologies, advocating for the rapid deployment of innovations despite potential ethical pitfalls. This ideology is rooted in the idea that faster technological advancement—similar to the mindset driving AI development—will yield solutions to pressing global challenges. However, critics argue that this approach risks overlooking necessary ethical considerations and public welfare. As biotechnology navigates its place within this framework, understanding the driving forces behind figures like He Jiankui and Ryan Shea becomes crucial in shaping regulations and public policy moving forward.
First, biotech veteran John Maraganore calls in to discuss his new startup, City Therapeutics, this week's Nobel Prize awards, and the nerdy accolade he just received. Then STAT's Megan Molteni tells us about "CRISPR baby" scientist He Jiankui and his new cryptocurrency financier.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
